TABLE 2.

Summary of baseline aerobic Gram-negative pathogens recovered from each patient in the ME population in the cUTI trials for ceftazidime-avibactam^a

Pathogen(s) in each patient (no. of patients)	Result (no. [%] of isolates)b
E. coli (55)	Screen negative (34 [61.8])
	Screen positive (21 [38.2])
	CTX-M-14 (2)
	CTX-M-15c (11)
	CTX-M-15 + OXA-1/30 (8)
E. cloacae (1)	AmpC overexpression (1)
E. coli-C. koseri (1)	Screen negative for E. coli (1) and C. koseri (1)
E. coli-P. mirabilis (1)	CTX-M-15 for E. coli (1) and screen negative for P. mirabilis (1)
P. mirabilis (1)	Screen negative (1)
P. aeruginosa (1)	Screen negative (1)
P. aeruginosa-E. coli (2)	Screen negative for P. aeruginosa (1) and E. coli (1)
	Screen negative for P. aeruginosa (1) and CTX-M-15 + OXA-1/30 for E. coli (1)

^aThe cUTI trial results shown represent 62 ME patients.

^bScreen negative, isolates that did not meet the MIC-based screening criteria; screen positive, isolates that met the screening criteria (i.e., ceftriaxone and/or ceftazidime MICs of ≥2 μg/ml, NF-GNB with ceftazidime MICs of ≥16 μg/ml, and Enterobacteriaceae and NF-GNB isolates exhibiting imipenem and meropenem MICs of ≥2 and ≥16 μg/ml, respectively). All Enterobacteriaceae and NF-GNB isolates had imipenem MICs of ≤0.25 and ≤2 μg/ml, respectively.

^cHyperproduction of the intrinsic AmpC enzyme was detected in one bla_CTX-M-15-carrying isolate.